logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure INF-9. Prevalence of markers of HBV infection estimated among national and subnational samples of injecting drug users 2004 to 2005, where data are available [see all figures in this series...]

Part (i) Percentage positive for ever infected (aHBc)


Dark square = samples with national coverage; blue triangle = samples with subnational (including local or regional) coverage.

Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.

Data for Italy and Austria are not prevalence of aHBc but prevalence of 'all HBV markers' as a proxy of aHBc prevalence.

Data for Portugal include non-IDUs and therefore may underestimate prevalence among IDUs (proportion of non-IDUs in the samples not known).

Data for Belgium and Portugal are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment.

In addition, data may not be representative for people who are in treatment - this is known to be the case for Belgium.

Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.

² - Data for Spain is from 2003; data for Netherlands is from 2000; data forIreland is from 2003; data for Portugal is from 2003.


SB2006: Figure Table INF-10 part (i)

For primary sources, study details and data before 2004, see Table INF-14 , Table INF-15, and Table INF-0.

See also 'General notes for interpreting data' on the Explanatory notes and help page.


Reitox national focal points

Page last updated: Friday, 23 November 2007